News | October 31, 2025
Merck’s Capvaxive shows strong momentum amid industry vaccine decline
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Guidelines aim to establish state-regulated veterinary blood banks
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Subscribe To Our Newsletter & Stay Updated
